Next Article in Journal
Update on Rapid Diagnostics for COVID-19: A Systematic Review
Previous Article in Journal
Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications
 
 
Article

Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients Suffering from COVID-19 Infection: An Observational Pilot Study

1
Associazione Sinerfit, 00199 Rome, Italy
2
Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy
3
Department of Experimental and Clinical Medicine, “Magna Graecia” University, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Bernhard Ryffel
Int. J. Transl. Med. 2022, 2(2), 242-251; https://doi.org/10.3390/ijtm2020022
Received: 5 May 2022 / Revised: 8 June 2022 / Accepted: 14 June 2022 / Published: 16 June 2022
Background: In the last two years, the COVID-19 pandemic has spread all over the world, affecting millions of people. The same infection can manifest in different clinical conditions, ranging from mild situations to severe patient impairment, up to their death. The COVID-19 infection can activate innate and adaptive immune systems and cause massive inflammatory responses that is important to treat as soon as possible. Methods: In the initial phase of the pandemic, a group of 240 unvaccinated subjects with COVID-19 disease was administered phytotherapy with immunostimulant and antioxidant property to evaluate the role of this phytotherapeutic preparation in counteracting the progression of the COVID-19 disease both in duration and complexity. Results: 161 patients were treated with phytotherapy alone and the prevailing symptoms in the acute phase were rhinitis, fever, cough, osteo-muscular pains; the other 79 patients were given a therapy with NSAIDs, symptomatic drugs, monoclonal antibodies, corticosteroids, antibiotics, and/or heparin. The coexistence of comorbidity (such as diabetes, hypertension, gastro-intestinal disease) was recorded in 74 out of 240 subjects, more frequently in the older subjects; there was no statistically significant correlation between the presence of comorbidity and the duration of disease. Hospitalization rate in this population was 1.6% and lethality rate was 0%. Conclusion: The use of phytotherapy can represent a valid weapon against COVID-19, since it showed no side effects and can also be used in association with other pharmacological therapies to reduce the massive inflammatory responses of this infection. View Full-Text
Keywords: population health; infectious diseases; phytotherapy population health; infectious diseases; phytotherapy
Show Figures

Figure 1

MDPI and ACS Style

Ortore, M.; Grazioli, E.; Tranchita, E.; Minganti, C.; Manteca, A.; Tinto, L.; Cerulli, C.; Fabi, I.; Foti, A.; Borriello, G.; Riondino, P.; Parisi, A. Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients Suffering from COVID-19 Infection: An Observational Pilot Study. Int. J. Transl. Med. 2022, 2, 242-251. https://doi.org/10.3390/ijtm2020022

AMA Style

Ortore M, Grazioli E, Tranchita E, Minganti C, Manteca A, Tinto L, Cerulli C, Fabi I, Foti A, Borriello G, Riondino P, Parisi A. Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients Suffering from COVID-19 Infection: An Observational Pilot Study. International Journal of Translational Medicine. 2022; 2(2):242-251. https://doi.org/10.3390/ijtm2020022

Chicago/Turabian Style

Ortore, Massimiliano, Elisa Grazioli, Eliana Tranchita, Carlo Minganti, Alessia Manteca, Ludovico Tinto, Claudia Cerulli, Igino Fabi, Antonella Foti, Giovanna Borriello, Paolo Riondino, and Attilio Parisi. 2022. "Evaluation of the Clinical Effects of an Antiviral, Immunostimulant and Antioxidant Phytotherapy in Patients Suffering from COVID-19 Infection: An Observational Pilot Study" International Journal of Translational Medicine 2, no. 2: 242-251. https://doi.org/10.3390/ijtm2020022

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop